



NewLink Genetics Corporation
Investor Relations Department
2503 South Loop Drive
Ames, IA 50010
United States

[Visit IR website](#) 
[Sign-up for Email alerts](#) 

Company Profile

Founded in 1999, NewLink Genetics is an immuno-oncology company focused on discovering and developing novel products for the treatment of cancer. The drug discovery and development teams at NewLink Genetics are relentlessly pursuing a wide range of immuno-oncology portfolio candidates with the potential to change the oncology landscape. NewLink Genetics' portfolio includes two small-molecule product candidates currently in clinical development. These product candidates inhibit the IDO pathway, a key immuno-oncology target, and focus on breaking the immune system's tolerance to cancer.

Press Releases [\[View all \]](#)

Jan 8, 2018

[NewLink Genetics Outlines 2018 Business Priorities to Support Phase 3 Pivotal Trial of Indoximod Plus PD-1 Inhibitors](#)

Dec 21, 2017

[NewLink Genetics to Present at the 36th Annual J.P. Morgan Healthcare Conference](#)

Nov 27, 2017

[NewLink Genetics to Participate in Upcoming Investor Conference](#)

Nov 20, 2017

[NewLink Genetics Announces the Presentation of Indoximod Data in Phase 1 Study for Children](#)

Nov 14, 2017

[NewLink Genetics Appoints Eugene Kennedy, M.D. as Chief Medical Officer](#)

Financials [\[View all \]](#)

[Third Quarter Financial Results](#)

Mar 6, 2017

[Annual Report \(10-K\)](#)

Mar 31, 2017

[Proxy Statement \(DEF 14A\)](#)

Nov 3, 2017

[Quarterly Report \(10-Q\)](#)

Aug 3, 2017

[Quarterly Report \(10-Q\)](#)

May 5, 2017

[Quarterly Report \(10-Q\)](#)